Drug intelligence / Profile preview

PCI020302

Development stage: Preclinical
Lead developer: Pattern Computer
Modality: Small Molecules

Overview

**PCI020302** is Pattern Computer's preclinical, AI-discovered combination therapy for **triple-negative breast cancer**. Pattern's patent portfolio identifies the combination as **idelalisib + defactinib**, intended to produce synergistic antitumor activity. Idelalisib inhibits phosphatidylinositol 3-kinase delta, while defactinib inhibits focal adhesion kinase and protein tyrosine kinase 2 beta. The candidate was discovered using Pattern Computer's PatternDE platform and has reported activity in preclinical animal models. ([patterncomputer.com](https://www.patterncomputer.com/pattern-expands-global-patent-protection-for-pci020302-across-u-s-mexico-europe-and-australia/))

Other names: idelalisib + defactinib

Targets

PIK3CD (Phosphatidylinositol 3-kinase delta)PTK2BFAK (Focal adhesion kinase)

Beyond the preview

Go deeper on PCI020302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCI020302.

Explore the full profile